Cytoprotective and antifibrotic effects of losartan on human orbital adipose-derived mesenchymal stem cells (hOA-MSCs) in an in vitro oxidative stress model
This study demonstrates that Losartan exerts concentration- and time-dependent cytoprotective and antifibrotic effects on human orbital adipose-derived mesenchymal stem cells under oxidative stress by enhancing proliferation, reducing reactive oxygen species, and modulating key gene expression pathways toward protective mechanisms.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When the surface of the eye is injured, whether by infection, a scratch, or surgery, the body's natural healing process can sometimes go too far. Instead of repairing the tissue cleanly, the body may lay down thick, scar-like tissue that clouds the cornea and steals away vision. This scarring is driven by a chaotic internal environment where the cells are overwhelmed by unstable molecules known as reactive oxygen species. These molecules act like rust inside the body, damaging cells and signaling them to build excessive, stiff tissue. To stop this, scientists are looking for ways to calm that internal storm and guide the healing cells back to a safe path. One promising candidate is a common blood pressure medication called Losartan. While doctors have long used it to protect the heart and kidneys, recent research suggests it might also have the power to stop the eye from scarring by helping cells survive this toxic environment and choose the right healing route.
In a new study, researchers set out to test exactly how Losartan works on the specific cells that live around the eye. They focused on human orbital adipose-derived mesenchymal stem cells. These are versatile repair cells found in the fatty tissue behind the eyelid, a source that is easily accessible as waste material from routine eyelid surgery. Because these cells can turn into various types of eye tissue, they are a perfect model for studying how the eye heals. The scientists created a controlled laboratory environment to mimic the damage caused by an eye injury. They exposed these stem cells to hydrogen peroxide, a chemical that creates the same kind of oxidative stress and cellular damage seen in a real injured eye. Once the cells were under this stress, the researchers introduced Losartan at various tiny doses to see if it could act as a shield.
The results showed that Losartan did more than just keep the cells alive; it actively cleaned up the damage. When the cells were treated with specific low doses of the drug, particularly at 2 nanomolar, 10 nanomolar, and 50 nanomolar, they not only survived the toxic stress but actually multiplied faster than untreated cells. More importantly, the drug acted as a powerful scavenger, clearing away the harmful reactive oxygen species that were threatening to destroy the cells. At the 2 nanomolar dose, the levels of these damaging molecules dropped so low that they were nearly identical to those in healthy, unstressed cells. This suggests that the drug successfully neutralized the internal rust that usually triggers scarring.
Beyond simply protecting the cells, the study revealed that Losartan changes the genetic instructions the cells follow. In a normal scarring response, cells receive signals to build stiff, fibrous tissue. The researchers found that Losartan shifted these signals toward a safer, anti-scarring path. The drug boosted the activity of a protective gene called SIRT1, which helps cells manage stress and survive. It also increased the activity of a receptor called AT2R, which is known to oppose the formation of scars. Perhaps most strikingly, the drug caused a massive surge in a specific protein called TGF-beta 3, which is famous for promoting clean healing without scarring, while simultaneously suppressing a gene called LOX that is responsible for cross-linking collagen into stiff scar tissue. This combination created a molecular environment where the cells were encouraged to heal smoothly rather than form a scar.
The study also uncovered a complex interaction between the drug and the genes that control blood vessel growth and tissue structure. While the drug reduced the expression of LOX, which is usually linked to the formation of new blood vessels, it actually increased the expression of a gene called VEGF at one specific dose. This unexpected pattern suggests that the drug might be uncoupling the usual link between tissue stiffening and blood vessel growth, allowing the eye to heal without the heavy, fibrous buildup that leads to blindness. The researchers noted that while the drug increased the levels of some proteins that typically drive scarring, the overall balance of signals strongly favored an anti-fibrotic outcome, likely because the protective mechanisms were so much stronger.
This work provides a clear picture of how a familiar medication might offer a new solution for a difficult eye problem. By using stem cells from the eye area and subjecting them to realistic stress, the researchers demonstrated that Losartan can act as a cytoprotective agent, shielding cells from damage and reprogramming them to avoid the fibrosis that ruins vision. The findings suggest that the drug works through a multi-layered defense: it clears out toxic molecules, boosts the cells' internal survival systems, and shifts their genetic programming away from scar formation. While this research was conducted in a laboratory setting and further testing is needed to confirm these effects in living patients, the results offer a compelling reason to explore Losartan as a potential treatment to prevent scarring on the surface of the eye.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.